Unique ID issued by UMIN | UMIN000021655 |
---|---|
Receipt number | R000024963 |
Scientific Title | Safety of a Coleus forskohlii formulation |
Date of disclosure of the study information | 2016/03/29 |
Last modified on | 2019/04/01 07:12:22 |
Safety of a Coleus forskohlii formulation
Dose escalation of a Coleus forskohlii formulation
Safety of a Coleus forskohlii formulation
Dose escalation of a Coleus forskohlii formulation
Japan |
obesity
Not applicable | Adult |
Others
NO
Coleus forskohlii (CF) is an Indian botanical which has been used in Ayurvedic medicine. Several small trials have reported the weight-loss effect by the CF extract. The purpose of the study is to evaluate safety of the CF extract in healthy subjects.
Safety
The primary outcome is safety evaluation as phase I. Adverse events are recorded daily basis until 1 week after the intervention. Physician's interview and the physical examinations at the basis and the completion of the intervention.
Subjective questionnaire (the preliminary observation period;1 week, the intervention period, and the post-intervention period;1 week.)
Interventional
Single arm
Non-randomized
Open -no one is blinded
Self control
1
Treatment
Food |
Administered escalating doses start from 110mg/day to 440mg/day. Each dose of a Coleus forskohlii formulation is administered for one week; ie oral intake of 1st wk is 110mg/day, 2nd wk is 220mg/day, 3rd wk is 330mg/day, and 4th wk is 440mg/day. A formulation contains 110mg of CF extract and 100mg of coconut oil per capsule. Each dose includes placebo capsule(s). Therefore, subjects take 4 capsules per day during the intervention.
20 | years-old | <= |
60 | years-old | >= |
Male and Female
- Age: more than or equal to 20 years at the time of providing informed consent
- Healthy individuals who have never experienced psychological and critical diseases.
- Healthy individuals who have the ability to provide written informed consent.
- Subjects who have an inappropriate clinical history for efficacy and safety assessment in the study (such as drug abuse, alcoholism, and the disease of heart, liver, kidney, lungs, eye, blood etc.) and who is taking any drugs.
- Subjects judged to be inappropriate for the study by the investigator.
30
1st name | Seika |
Middle name | |
Last name | Kamohara |
DHC Corporation
Division of Research Adviser
1060047
Minami-azabu 2-7-1, Minato-ku, Tokyo
0354423945
kamohara-seika@umin.ac.jp
1st name | Seika |
Middle name | |
Last name | Kamohara |
DHC Corporation
Division of Research Adviser
106-0047
Minami-azabu 2-7-1, Minato-ku, Tokyo
0354423945
kamohara@dhc.co.jp
DHC Corporation
DHC Corporation
Profit organization
Suidobashi Medical Clinic
DHC Corporation Life Science Division
Azabudai 1-5-7, Minatoku, Tokyo, Japan
0335852571
denpo@dhc.co.jp
NO
2016 | Year | 03 | Month | 29 | Day |
https://www.sciencedirect.com/science/article/abs/pii/S2186495016000055?via%3Dihub
Unpublished
https://www.sciencedirect.com/science/article/abs/pii/S2186495016000055?via%3Dihub
29
https://www.sciencedirect.com/science/article/abs/pii/S2186495016000055?via%3Dihub
2019 | Year | 04 | Month | 01 | Day |
https://www.sciencedirect.com/science/article/abs/pii/S2186495016000055?via%3Dihub
https://www.sciencedirect.com/science/article/abs/pii/S2186495016000055?via%3Dihub
https://www.sciencedirect.com/science/article/abs/pii/S2186495016000055?via%3Dihub
https://www.sciencedirect.com/science/article/abs/pii/S2186495016000055?via%3Dihub
Completed
2016 | Year | 02 | Month | 28 | Day |
2016 | Year | 02 | Month | 27 | Day |
2016 | Year | 03 | Month | 29 | Day |
2018 | Year | 03 | Month | 01 | Day |
2016 | Year | 03 | Month | 28 | Day |
2019 | Year | 04 | Month | 01 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024963